Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Fiche publication
Date publication
janvier 2018
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent
Tous les auteurs :
Maunoury F, Clément A, Nwankwo C, Levy-Bachelot L, Abergel A, Di Martino V, Thervet E, Durand-Zaleski I
Lien Pubmed
Résumé
To assess the cost-effectiveness of the elbasvir/grazoprevir (EBR/GZR) regimen in patients with genotype 1 chronic hepatitis C virus (HCV) infection with severe and end-stage renal disease compared to no treatment.
Mots clés
Antiviral Agents, economics, Benzofurans, economics, Cost-Benefit Analysis, methods, Drug Therapy, Combination, economics, Female, France, Genotype, Hepacivirus, genetics, Hepatitis C, Chronic, complications, Humans, Imidazoles, economics, Kidney Failure, Chronic, complications, Liver Cirrhosis, complications, Male, Middle Aged, Models, Economic, Quality-Adjusted Life Years, Quinoxalines, economics, RNA, Viral, genetics, Randomized Controlled Trials as Topic, Renal Dialysis
Référence
PLoS ONE. 2018 ;13(3):e0194329